mesothelioma study 2
mesothelioma study 2
Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.
Truong MT, Marom EM, Erasmus JJ.
Department of Diagnostic Imaging, Unit 57, University of Texas M.D.
Anderson Cancer Center, Houston, TX 77030, USA. mtruong@mdanderson.org
PURPOSE: Malignant pleural mesothelioma (MPM) is an uncommon
neoplasm arising from mesothelial cells of the pleura. The prognosis is
poor with a median survival of 8 to 18 months after diagnosis.
Multimodality regimens combining chemotherapy, radiotherapy,
immunotherapy, and surgery are being used more frequently in patient
management. Extrapleural pneumonectomy is the surgical treatment of
choice in 10% to 15% of patients who present with resectable disease and
is reported to prolong survival. Accurate staging is important to
distinguish patients who are resectable from those requiring palliative
therapy. Integrated computed tomography-positron emission tomography
(CT-PET) increases the accuracy of overall staging in patients with MPM
and significantly improves the selection of patients for curative
surgical resection. Specifically, CT-PET detects more extensive disease
involvement than that shown by other imaging modalities and is
particularly useful in identifying occult distant metastases. This
article reviews aspects of imaging performed in the initial staging of
patients with MPM according to the International Mesothelioma Interest
Group staging system and will emphasize the appropriate role of CT-PET
imaging in determining the T, N, and M descriptors.
0 comments:
Post a Comment